GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsGuangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study for BAT2506, a proposed biosimilar of Simponi® (golimumab). The clinical study is a randomized, double-blind, par...
The comparative study met its primary endpoints and showed equivalent efficacy and comparable safety profile in patients with moderate-to-severe rheumatoid arthritis . CAMBRIDGE, Mass. and GUANGZHOU, China, June 01, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (6...
April 8th 2021, Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced that they entered into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a Phase 3 clinical stage anti-interleukin-6 (IL-6) receptor monoclonal antibody tha...
